Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-dose chemotherapy followed by short-course blinatumomab in newly diagnosed adult B-ALL
ChiCTR2600126853Phase 2Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Jun 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of blinatumomab in acute lymphoblastic leukemia (ALL), sponsored by Henan Cancer Hospital. Primary endpoints: Objective Response Rate (ORR) and MRD Clearance Rate. Started Jun 2026; status: recruiting.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on ChiCTR2600126853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126853.